Muscarinic Agonists for the Treatment of Cognition in Schizophrenia
Angela K. Sellin, MD, Mujeeb Shad, MD, and Carol Tamminga, MD
CNS Spectr. 2008;13(11):985-996
It is widely accepted that cholinergic activity at muscarinic receptors is required to maintain cognitive functions, including learning and memory.
Memory domains are especially impaired in schizophrenia, which may explain difficulties in psychosocial rehabilitation of individuals with this illness. However, little is known about the mechanism of this impairment.”
http://www.cnsspectrums.com/userdocs/articleimages/144/1108CNS_Sellin_table2big.jpg
